Loading stock data…
CRDF
$1.52+0.02 (+1.33%)
Market OpenUpdated 3:43 PM EDT
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cardiff Oncology, Inc. in the Healthcare sector is trading at $1.52. Wall Street consensus targets $5.36 (7 analysts), implying a +252.4% move over the next 12 months. The stock is currently near its 52-week low of $1.35, remaining 25.9% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +252.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$1.52
Potential Downside
0%
Whystock Fair Value$1.52
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Buy
Mean target$5.36+252.4%
Range$2.00 – $12.00
Fundamentals
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treatin...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-128.96%
Volume
Today's trading volume
975,195
Recent News
Cardiff Oncology And 2 Other Promising Penny Stocks For Your Watchlist
Over the last 7 days, the U.S. market has dropped by 1.0%, yet it has risen by 23% over the past year, with earnings forecasted to grow annually by 17%. In such a fluctuating market, identifying stocks with strong fundamentals and growth potential is crucial for investors seeking stability and opportunity. While "penny stocks" may sound like an outdated term, they continue to represent smaller or less-established companies that can offer significant value; we've identified three such stocks...
Cardiff Oncology Showcases Onvansertib: 72% ORR Signal in Phase II RAS-Mutant mCRC Webinar
Cardiff Oncology (NASDAQ:CRDF) interim CEO Mani Mohindru outlined updated clinical results and development plans for the company’s investigational PLK1 inhibitor onvansertib during a webinar focused on first-line RAS-mutated metastatic colorectal cancer (mCRC), a population she described as having s
Cardiff Oncology Spotlights Onvansertib Data at Oppenheimer: 72% ORR in RAS-Mutant mCRC
Cardiff Oncology (NASDAQ:CRDF) used an appearance at Oppenheimer’s 36th Annual Healthcare Conference to highlight updated clinical results and its development plans for onvansertib, an oral, highly selective polo-like kinase 1 (PLK1) inhibitor being studied in RAS-mutated metastatic colorectal cance
Cardiff Oncology: Q4 Earnings Snapshot
SAN DIEGO (AP) — Cardiff Oncology, Inc. CRDF) on Tuesday reported a loss of $7.2 million in its fourth quarter. On a per-share basis, the San Diego-based company said it had a loss of 11 cents.
Cardiff Oncology (CRDF) Is Down 43.9% After Advancing Onvansertib And Reshuffling Leadership Team
Cardiff Oncology recently reported positive dose-dependent Phase 2 data for onvansertib in first-line RAS‑mutated metastatic colorectal cancer and outlined plans to move the 30 mg dose into a registrational trial, while simultaneously announcing a leadership reshuffle including a new interim CEO and the departure of its CFO as of January 27, 2026. The combination of advancing onvansertib toward potential late-stage development and installing an experienced biotech operator as interim CEO...